Nerve cells made lab-grown glioblastoma respond to a chemo drug
Original title: Glioblastoma - Neuroblastoma co-cultured multicellular spheroid model for evaluating Temozolomide response
How far along is this research?
This is a preprint. Other scientists have not checked it yet, so treat it as an early signal rather than an answer.
This was only done with cells grown in a lab dish.
The short version
In a lab dish, brain tumor cells mixed with nerve cells responded better to chemo.
What was studied. Researchers grew tiny 3D balls of glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary cells, nerve type cells, or both mixed together. They tested the drug temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary on the balls over 14 days.
What they found. The mixed balls grew into the same tight, drug resistant shape as the tumor only balls. Even so, the mixed balls responded to the drug at every dose tested. The balls made of just one cell type did not respond at the highest dose.
What this means, and what it doesn't
What it could mean: This may help explain why some lab results do not match what happens in people. Lab tests that leave nerve cells out may miss how a drug really acts in the brain.
What it doesn't mean: This was done in cells in a dish, not in people or animals. It is not a new treatment, and it does not change how temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary is used today. It is very far from everyday care, and it is not a cure or a promise of one.
Source: bioRxiv (preprint), August 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.